These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 39144633)

  • 1. Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration's adverse event reporting system databases.
    Liang Q; Liao X; Wu H; Huang Y; Liang T; Li H
    Front Pharmacol; 2024; 15():1431562. PubMed ID: 39144633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ubrogepant and rimegepant: signal detection using spontaneous reports of adverse events from the Food and Drug Administration Adverse Event Reporting System.
    Battini V; Carnovale C; Clementi E; Sessa M
    Expert Opin Drug Saf; 2023; 22(11):1105-1112. PubMed ID: 37293948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system.
    Sun W; Li Y; Xia B; Chen J; Liu Y; Pang J; Liu F; Cheng H
    Front Pharmacol; 2023; 14():1257282. PubMed ID: 38264523
    [No Abstract]   [Full Text] [Related]  

  • 4. A disproportionality analysis for assessing the safety of FLT3 inhibitors using the FDA Adverse Event Reporting System (FAERS).
    Zhou J; Zhang J; Wang Q; Peng M; Qian Y; Wu F; Rao Q; DanZhen L; Yang Y; Wang S; Liu M
    Ther Adv Drug Saf; 2024; 15():20420986241284105. PubMed ID: 39381060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse event profiles of CDK4/6 inhibitors: data mining and disproportionality analysis of the FDA adverse event reporting system.
    Shen J; Luo P; Xu J
    Ther Adv Drug Saf; 2024; 15():20420986241278498. PubMed ID: 39376495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raynaud's phenomenon associated with calcitonin gene-related peptide receptor antagonists case report.
    Bedrin K; Ailani J; Dougherty C
    Headache; 2022 Nov; 62(10):1419-1423. PubMed ID: 36426766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gepants - a long way to cure: a narrative review.
    Altamura C; Brunelli N; Marcosano M; Fofi L; Vernieri F
    Neurol Sci; 2022 Sep; 43(9):5697-5708. PubMed ID: 35650458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database.
    Yang Q; Wang J; Wang M; Zhang S; He QQ
    BMC Pharmacol Toxicol; 2024 Sep; 25(1):64. PubMed ID: 39267168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-marketing safety concerns with rimegepant based on a pharmacovigilance study.
    Hu JL; Wu JY; Xu S; Qian SY; Jiang C; Zheng GQ
    J Headache Pain; 2024 Oct; 25(1):169. PubMed ID: 39375581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world study of antifibrotic drugs-related adverse events based on the United States food and drug administration adverse event reporting system and VigiAccess databases.
    He M; Yang T; Zhou J; Wang R; Li X
    Front Pharmacol; 2024; 15():1310286. PubMed ID: 38464722
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
    Zhao D; Long X; Zhou J; Wang J
    Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacotherapeutic management of episodic and chronic migraine with gepants.
    Tajti J; Szok D; Csáti A; Vécsei L
    Expert Opin Pharmacother; 2023 Jun; 24(8):947-958. PubMed ID: 37038933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
    Zhang S; Wang Y; Qi Z; Tong S; Zhu D
    Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcitonin gene-related peptide-targeting drugs and Raynaud's phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database.
    Gérard AO; Merino D; Van Obberghen EK; Rocher F; Destere A; Lantéri-Minet M; Drici MD
    J Headache Pain; 2022 May; 23(1):53. PubMed ID: 35505285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Brief Review of Gepants.
    Li D; Abreu J; Tepper SJ
    Curr Pain Headache Rep; 2023 Sep; 27(9):479-488. PubMed ID: 37531032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse event signal mining and serious adverse event influencing factor analysis of fulvestrant based on FAERS database.
    Yin G; Song G; Xue S; Liu F
    Sci Rep; 2024 May; 14(1):11367. PubMed ID: 38762547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review.
    Rissardo JP; Caprara ALF
    Brain Sci; 2022 Nov; 12(12):. PubMed ID: 36552072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023.
    Yang Y; Wei S; Tian H; Cheng J; Zhong Y; Zhong X; Huang D; Jiang C; Ke X
    Front Pharmacol; 2024; 15():1439115. PubMed ID: 39101151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.